Back to Trials
NCT07339254Recruiting

Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

University of Southern California

Start Date

3/12/2026

Completion Date

3/12/2028

Summary

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

Detailed Description

PRIMARY OBJECTIVES: I. To assess patient satisfaction with receiving IV immune checkpoint inhibitors, reflecting whether the patient thought that the experience was safe, convenient, comfortable and proceeded smoothly. II. To assess patient preference for IV versus home SC ICI administration. OUTLINE: This is an observational study. Patients complete surveys on study.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * \* Age ≥ 18 years. * \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy) * \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint. * \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent. Exclusion Criteria: * \* Patients is unable to consent for themselves * \* Patient has not yet completed the 1st cycle of ICI-based therapy

Interventions

OTHER

Non-Interventional Study

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Lung Non-Small Cell Carcinoma

Locations

Los Angeles General Medical Center

Los Angeles, California 90033

United States

USC / Norris Comprehensive Cancer Center

Los Angeles, California 90033

United States